Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Get Free Report) was the target of a significant drop in short interest in the month of October. As of October 30th, there was short interest totaling 6,660 shares, a drop of 46.0% from the October 15th total of 12,328 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 28,516 shares, the days-to-cover ratio is currently 0.2 days.
Regentis Biomaterials Stock Performance
RGNT traded down $0.04 during trading on Wednesday, hitting $1.19. 3,657 shares of the company’s stock were exchanged, compared to its average volume of 1,567,091. Regentis Biomaterials has a fifty-two week low of $1.14 and a fifty-two week high of $15.50. The business’s 50 day moving average is $1.59 and its two-hundred day moving average is $2.62.
Regentis Biomaterials (NYSEAMERICAN:RGNT – Get Free Report) last announced its earnings results on Friday, September 11th. The company reported ($0.22) earnings per share (EPS) for the quarter.
Regentis Biomaterials Company Profile
Regentis Biomaterials is a medical technology company developing biomaterials for the repair of damaged cartilage. Its lead product, GelrinC, is an implant designed to treat focal cartilage defects in the knee. The cell-free hydrogel is placed in the defect and is intended to support the formation of repair tissue as the material gradually degrades. The company’s work focuses on providing an off-the-shelf alternative to cartilage-repair procedures that require harvesting a patient’s cells or tissue.
Further Reading
- Five stocks we like better than Regentis Biomaterials
- Palantir’s Political Controversy Is Hiding a Much Bigger Story
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
Receive News & Ratings for Regentis Biomaterials Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regentis Biomaterials and related companies with MarketBeat.com's FREE daily email newsletter.
